Popular Articles
Cellulite Cream

QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) In Postmenopausal Vaginal Atrophy
QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, announced positive top-line efficacy results from the first of two patient cohorts in its second pivotal Phase 3 trial of the investigational compound, Ophena(TM) (ospemifene tablets), for the treatment of postmenopausal vulvovaginal atrophy (VVA). The Company has also successfully completed two long term safety extension studies from its first pivotal Phase 3 studies. QuatRx intends to use these results in support of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in early 2010 seeking approval for Ophena(TM), a new SERM (selective estrogen receptor modulator) for the treatment of the symptoms of vulvovaginal atrophy. Ophena(TM) is the only non-estrogen therapy currently in late-stage development for the treatment of vaginal symptoms associated with menopause.
generic viagra online
Catholic Law Professors Debate Obama Administration's Efforts To Reduce Need For Abortion
Catholic constitutional law professors Doug Kmiec of the Pepperdine University School of Law and Robert George of Princeton University on Thursday during a forum at the National Press Club debated the Obama administration"s abortion policies and whether opposing sides in the abortion-rights debate should work toward finding "common ground," the Washington Times reports. Kmiec -- a Republican who broke rank with many Catholics and supported President Obama"s run for the presidency -- stressed that the president is serious about reducing the need for abortion. However, George "challenged the administration to do something concrete," such as ban certain abortion procedures, according to the Times. He said that Obama "rejects what we and pro-lifers propose is common ground. ... He does not believe human beings acquire rights until after birth."Kmiec and George also debated the role of Catholics in politics, such as whether Catholics who support abortion rights should be denied Holy Communion or whether Catholic bishops should speak out against politicians who support abortion rights. In April 2008, a Los Angeles priest denied Kmiec Communion because of his support for Obama. Kmiec asked, "Are we as Catholics expected to sit on the sidelines aloof with the truth talking to ourselves or are we to engage our fellow citizens and offer that faith? The 2008 election was very much a test of that." He said that he does not believe that intimidation is the correct way to address abortion-rights issues, adding that the "denial of Communion is intimidation." Kmiec said that Catholic bishops" opposition to abortion-rights supporters who are Catholic "is not either an effective nor a Catholic approach. Nor is it a Catholic approach to endorse candidates. Yet certain bishops endorse candidates. Nor should churches allow materials in their vestibule saying it is a sin of the highest order to cast a vote for Barack Obama." He noted that 54% of Catholics voted for Obama.George opted to focus on Obama"s legislative record instead of the issue of Catholics in politics. He said, "Obama"s record as an activist, legislator and now as president is that an unborn baby possesses no rights. Throughout his career, he has denied every fundamental legislation that would discourage its practice or limit its liability" (Duin, Washington Times, 5/29).
News of the day
First Viable Treatment Option For Highly Resistant Form Of CML May Be Provided By ChemGenex's Omacetaxine
ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The open label Phase 2/3 study (CGX-635-CML-202) investigated the use of omacetaxine, administered subcutaneously in CML patients who had failed imatinib and who have the highly drug resistant T315I kinase domain mutation.
Nutrition

Inflammatory Molecules Promote Liver Scarring

Scarring of the liver, which can progress to cirrhosis and/or cancer of the liver, is caused by persistent liver damage, such as occurs in those with untreated hepatitis C or alcoholism. Although such scarring (fibrosis) develops in an inflammatory environment, the role of inflammatory molecules has not been well defined. However, a team of researchers at Columbia University, New York, and UCSD, La Jolla, has established that the proteins CCR1 and CCR5 and the soluble inflammatory molecules that bind to them promote the development of liver fibrosis in mice. The team, led by Robert Schwabe and Ekihiro Seki, observed that expression of the inflammatory molecules MIP-1-alpha, MIP-1-beta, and RANTES, and the proteins to which they bind (CCR1 and CCR5), was increased in 2 mouse models of liver fibrosis. Consistent with a role for these molecules in the development of liver fibrosis, preventing the inflammatory molecules binding CCR1 and CCR5 reduced liver fibrosis, as did eliminating expression of either CCR1 or CCR5. The latter experiments also identified the cells on which CCR1 and CCR5 expression is important for promoting liver fibrosis. As expression of RANTES, CCR1, and CCR5 was detected in the livers of patients with cirrhosis, the authors suggest that targeting CCR1 and CCR5 (for which there are already small molecule inhibitors in clinical development) might be a viable approach to prevent liver fibrosis. TITLE: CCR1 and CCR5 promote hepatic fibrosis in mice AUTHORS: Robert F. Schwabe Columbia University, New York, New York, USA. Ekihiro Seki University of California, San Diego, La Jolla, California, USA. View the PDF of this article at: https://www.the-jci.org/article.php?id=37444 Karen Honey Journal of Clinical Investigation JCI online early table of contents: June 15, 2009


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):